{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T09:06:02Z","timestamp":1779527162869,"version":"3.53.1"},"reference-count":119,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["812915"],"award-info":[{"award-number":["812915"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["310030_215043"],"award-info":[{"award-number":["310030_215043"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ymthe.2025.08.037","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:54:49Z","timestamp":1756277689000},"page":"5383-5400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Orf virus-based vectors induce potent germinal center B cell, Tfh cell, and CD8+ T cell responses"],"prefix":"10.1016","volume":"33","author":[{"given":"Anna Lena","family":"Kastner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Friederike","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirela","family":"Dimitrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doron","family":"Merkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Amann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1594-3189","authenticated-orcid":false,"given":"Daniel D.","family":"Pinschewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.08.037_bib1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-021-01301-0","article-title":"Vaccine development for emerging infectious diseases","volume":"27","author":"Excler","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.08.037_bib2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-immunol-120419-022408","article-title":"Germinal Centers","volume":"40","author":"Victora","year":"2022","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib3","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cell.2019.03.016","article-title":"B Cell Responses: Cell Interaction Dynamics and Decisions","volume":"177","author":"Cyster","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.08.037_bib4","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","article-title":"Duration of humoral immunity to common viral and vaccine antigens","volume":"357","author":"Amanna","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.08.037_bib5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1749-6632.1996.tb52958.x","article-title":"Long-term antibody production is sustained by antibody-secreting cells in the bone marrow following acute viral infection","volume":"797","author":"Slifka","year":"1996","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ymthe.2025.08.037_bib6","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1128\/jvi.69.3.1895-1902.1995","article-title":"Bone marrow is a major site of long-term antibody production after acute viral infection","volume":"69","author":"Slifka","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41577-023-00897-3","article-title":"Memory B cells","volume":"24","author":"Inoue","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib8","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1084\/jem.20110740","article-title":"Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants","volume":"208","author":"Purtha","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2025.08.037_bib9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/intimm\/dxz049","article-title":"Requirement for memory B-cell activation in protection from heterologous influenza virus reinfection","volume":"31","author":"Leach","year":"2019","journal-title":"Int. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib10","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.immuni.2020.09.001","article-title":"Affinity-Restricted Memory B Cells Dominate Recall Responses to Heterologous Flaviviruses","volume":"53","author":"Wong","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.08.037_bib11","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T Follicular Helper Cell Biology: A Decade of Discovery and Diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.08.037_bib12","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.08.037_bib13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-022-04465-y","article-title":"Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron","volume":"603","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.08.037_bib14","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","volume":"27","author":"Apostolidis","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.08.037_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ymthe.2025.08.037_bib16","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.08.037_bib17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/d41586-019-03490-8","article-title":"\u2018Make Ebola a thing of the past\u2019: first vaccine against deadly virus approved","volume":"575","author":"Callaway","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.08.037_bib18","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.08.037_bib19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.08.037_bib20","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1\u20132a Trial of Ad26.COV2.S Covid-19 Vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.08.037_bib21","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jama.2021.3645","article-title":"Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19","volume":"325","author":"Stephenson","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2025.08.037_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.08.037_bib23","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2025.08.037_bib24","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib25","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/509258","article-title":"Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector","volume":"194","author":"Catanzaro","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.08.037_bib26","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.vaccine.2009.10.091","article-title":"Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive","volume":"28","author":"Hutnick","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2025.08.037_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/hum.2013.2527","article-title":"Adenovirus: The First EffectiveIn VivoGene Delivery Vector","volume":"25","author":"Crystal","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.08.037_bib28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41541-024-00895-z","article-title":"Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines","volume":"9","author":"Gardner","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ymthe.2025.08.037_bib29","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/JVI.01689-07","article-title":"Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy","volume":"82","author":"Leen","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/infdis\/jiz071","article-title":"Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya","volume":"220","author":"Mutua","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.08.037_bib31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.08.037_bib32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/infdis\/jiaa586","article-title":"Safety and Immunogenicity of Heterologous and Homologous Two Dose Regimens of Ad26- and MVA-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study","volume":"226","author":"Goldstein","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.08.037_bib33","article-title":"First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster","volume":"12","author":"Esen","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2025.08.037_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.70038","article-title":"Advancing ORFV-Based Therapeutics to the Clinical Stage","volume":"35","author":"Helmold","year":"2025","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib35","first-page":"311","article-title":"Ovine diseases","volume":"29","author":"Haig","year":"1998","journal-title":"Vet. Res."},{"key":"10.1016\/j.ymthe.2025.08.037_bib36","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3390\/vaccines12050492","article-title":"Pharmacokinetic and Environmental Risk Assessment of Prime-2-CoV, a Non-Replicating Orf Virus-Based Vaccine against SARS-CoV-2","volume":"12","author":"Metz","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.ymthe.2025.08.037_bib37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2460\/ajvr.1984.45.02.263","article-title":"Contagious ecthyma virus-vaccination failures","volume":"45","author":"Buddle","year":"1984","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.ymthe.2025.08.037_bib38","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1128\/JVI.02470-12","article-title":"A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein","volume":"87","author":"Amann","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib39","doi-asserted-by":"crossref","first-page":"D708","DOI":"10.1093\/nar\/gkx932","article-title":"Virus taxonomy: the database of the International Committee on Taxonomy of Viruses (ICTV)","volume":"46","author":"Lefkowitz","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.08.037_bib40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1439-0450.2002.00539.x","article-title":"Parapoxviruses: from the lesion to the viral genome","volume":"49","author":"Buttner","year":"2002","journal-title":"J. Vet. Med. B Infect Dis. Vet. Public Health"},{"key":"10.1016\/j.ymthe.2025.08.037_bib41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0168-1656(99)00141-8","article-title":"Parapoxviruses: potential alternative vectors for directing the immune response in permissive and non-permissive hosts","volume":"73","author":"Rziha","year":"1999","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0168-1656(00)00307-2","article-title":"Generation of recombinant parapoxviruses: non-essential genes suitable for insertion and expression of foreign genes","volume":"83","author":"Rziha","year":"2000","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/v11020127","article-title":"Genomic Characterization of Orf Virus Strain D1701-V (Parapoxvirus) and Development of Novel Sites for Multiple Transgene Expression","volume":"11","author":"Rziha","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.08.037_bib44","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0147-9571(03)00019-5","article-title":"Poxviruses as vaccine vectors","volume":"26","author":"Pastoret","year":"2003","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.08.037_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.873351","article-title":"Orf Virus-Based Vectors Preferentially Target Professional Antigen-Presenting Cells, Activate the STING Pathway and Induce Strong Antigen-Specific T Cell Responses","volume":"13","author":"Muller","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1322879","article-title":"Immunogenicity of chimeric hemagglutinins delivered by an orf virus vector platform against swine influenza virus","volume":"15","author":"do Nascimento","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib47","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1016\/j.vaccine.2006.05.078","article-title":"Prime-boost immunization using DNA vaccine and recombinant Orf virus protects pigs against Pseudorabies virus (Herpes suid 1)","volume":"24","author":"Dory","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2025.08.037_bib48","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1128\/JVI.77.17.9312-9323.2003","article-title":"Novel recombinant parapoxvirus vectors induce protective humoral and cellular immunity against lethal herpesvirus challenge infection in mice","volume":"77","author":"Fischer","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.747574","article-title":"Protective Efficacy of an Orf Virus-Vector Encoding the Hemagglutinin and the Nucleoprotein of Influenza A Virus in Swine","volume":"12","author":"Joshi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083802","article-title":"New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus","volume":"8","author":"Rohde","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.08.037_bib51","doi-asserted-by":"crossref","first-page":"9256","DOI":"10.1016\/j.vaccine.2011.09.121","article-title":"A new recombinant Orf virus (ORFV, Parapoxvirus) protects rabbits against lethal infection with rabbit hemorrhagic disease virus (RHDV)","volume":"29","author":"Rohde","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2025.08.037_bib52","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.1016\/j.vaccine.2007.05.035","article-title":"Efficient priming against classical swine fever with a safe glycoprotein E2 expressing Orf virus recombinant (ORFV VrV-E2)","volume":"25","author":"Voigt","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2025.08.037_bib53","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3390\/vaccines8020295","article-title":"Orf Virus-Based Vaccine Vector D1701-V Induces Strong CD8+ T Cell Response against the Transgene but Not against ORFV-Derived Epitopes","volume":"8","author":"Reguzova","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2025.08.037_bib54","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1128\/JVI.79.1.314-325.2005","article-title":"Prevention of virus persistence and protection against immunopathology after Borna disease virus infection of the brain by a novel Orf virus recombinant","volume":"79","author":"Henkel","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib55","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri1783","article-title":"Antiviral antibody responses: the two extremes of a wide spectrum","volume":"6","author":"Hangartner","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib56","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1172\/JCI200422374","article-title":"Kinetics of protective antibodies are determined by the viral surface antigen","volume":"114","author":"Pinschewer","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.08.037_bib57","first-page":"1","article-title":"Lymphocytic choriomeningitis virus and immunology","volume":"263","author":"Zinkernagel","year":"2002","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib58","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2318657121","article-title":"Central tolerance shapes the neutralizing B cell repertoire against a persisting virus in its natural host","volume":"121","author":"Florova","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.08.037_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005276","article-title":"Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection","volume":"11","author":"Sommerstein","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2025.08.037_bib60","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1074-7613(00)80277-0","article-title":"The Role of Somatic Mutation in the Generation of the Protective Humoral Immune Response against Vesicular Stomatitis Virus","volume":"5","author":"Kalinke","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.08.037_bib61","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1135710","article-title":"Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G","volume":"315","author":"Roche","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.08.037_bib62","doi-asserted-by":"crossref","first-page":"13263","DOI":"10.1073\/pnas.230417497","article-title":"Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs","volume":"97","author":"Ochsenbein","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.08.037_bib63","doi-asserted-by":"crossref","first-page":"11650","DOI":"10.1128\/JVI.00955-07","article-title":"Early antibodies specific for the neutralizing epitope on the receptor binding subunit of the lymphocytic choriomeningitis virus glycoprotein fail to neutralize the virus","volume":"81","author":"Eschli","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib64","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.celrep.2019.12.023","article-title":"Chronic Viral Infection Promotes Efficient Germinal Center B Cell Responses","volume":"30","author":"Fallet","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2025.08.037_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aah3565","article-title":"Type I interferon suppresses virus-specific B cell responses by modulating CD8(+) T cell differentiation","volume":"1","author":"Moseman","year":"2016","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib66","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aah6789","article-title":"Inflammatory monocytes hinder antiviral B cell responses","volume":"1","author":"Sammicheli","year":"2016","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib67","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1073\/pnas.1401662111","article-title":"Type I interferon suppresses de novo virus-specific CD4 Th1 immunity during an established persistent viral infection","volume":"111","author":"Osokine","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.08.037_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.908707","article-title":"Adoptive B cell therapy for chronic viral infection","volume":"13","author":"Chung","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib69","doi-asserted-by":"crossref","first-page":"12883","DOI":"10.1073\/pnas.2135542100","article-title":"Antiviral immune responses in gene-targeted mice expressing the immunoglobulin heavy chain of virus-neutralizing antibodies","volume":"100","author":"Hangartner","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.08.037_bib70","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1128\/JVI.72.3.2253-2258.1998","article-title":"Enhanced virus clearance by early inducible lymphocytic choriomeningitis virus-neutralizing antibodies in immunoglobulin-transgenic mice","volume":"72","author":"Seiler","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib71","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aah6817","article-title":"Interferon-driven deletion of antiviral B cells at the onset of chronic infection","volume":"1","author":"Fallet","year":"2016","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib72","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1084\/jem.20051557","article-title":"Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread","volume":"203","author":"Hangartner","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2025.08.037_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110303","article-title":"Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors","volume":"38","author":"Sahin","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2025.08.037_bib74","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41586-019-0879-y","article-title":"Commonality despite exceptional diversity in the baseline human antibody repertoire","volume":"566","author":"Briney","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.08.037_bib75","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1074-7613(00)80470-7","article-title":"Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection","volume":"8","author":"Murali-Krishna","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.08.037_bib76","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/90950","article-title":"Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory","volume":"7","author":"Homann","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.08.037_bib77","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.immuni.2007.07.010","article-title":"Inflammation Directs Memory Precursor and Short-Lived Effector CD8+ T Cell Fates via the Graded Expression of T-bet Transcription Factor","volume":"27","author":"Joshi","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.08.037_bib78","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/ni1009","article-title":"Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells","volume":"4","author":"Kaech","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib79","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1099\/0022-1317-76-2-381","article-title":"Role of virus and host variables in virus persistence or immunopathological disease caused by a non-cytolytic virus","volume":"76","author":"Moskophidis","year":"1995","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib80","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1084\/jem.156.1.79","article-title":"Lymphocytic choriomeningitis virus killer T cells are lethal only in weakly disseminated murine infections","volume":"156","author":"Pfau","year":"1982","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2025.08.037_bib81","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1084\/jem.174.6.1425","article-title":"Immune response against lymphocytic choriomeningitis virus infection in mice without CD8 expression","volume":"174","author":"Fung-Leung","year":"1991","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2025.08.037_bib82","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1128\/jvi.61.6.1867-1874.1987","article-title":"Mechanism of recovery from acute virus infection: treatment of lymphocytic choriomeningitis virus-infected mice with monoclonal antibodies reveals that Lyt-2+ T lymphocytes mediate clearance of virus and regulate the antiviral antibody response","volume":"61","author":"Moskophidis","year":"1987","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib83","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1749-6632.1988.tb36343.x","article-title":"Recovery from acute virus infection. Role of cytotoxic T lymphocytes in the elimination of lymphocytic choriomeningitis virus from spleens of mice","volume":"532","author":"Lehmann-Grube","year":"1988","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ymthe.2025.08.037_bib84","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0167-5699(00)01612-1","article-title":"The prime-boost strategy: exciting prospects for improved vaccination","volume":"21","author":"Ramshaw","year":"2000","journal-title":"Immunol. Today"},{"key":"10.1016\/j.ymthe.2025.08.037_bib85","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/eji.1830260943","article-title":"Immunity to viruses in B cell-deficient mice: influence of antibodies on virus persistence and on T cell memory","volume":"26","author":"Brundler","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib86","doi-asserted-by":"crossref","first-page":"13407","DOI":"10.1128\/JVI.77.24.13407-13411.2003","article-title":"Detailed Analysis of the CD8 + T-Cell Response following Adenovirus Vaccination","volume":"77","author":"Yang","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib87","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1182\/blood-2007-02-062117","article-title":"Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines","volume":"110","author":"Tatsis","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.08.037_bib88","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.2447","article-title":"CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.08.037_bib89","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.4049\/jimmunol.1202861","article-title":"Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-Simian-and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization","volume":"190","author":"Quinn","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib90","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1172\/JCI78280","article-title":"Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling","volume":"125","author":"Quinn","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.08.037_bib91","article-title":"Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack","volume":"2","author":"Bonilla","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2025.08.037_bib92","doi-asserted-by":"crossref","first-page":"8431","DOI":"10.4049\/jimmunol.175.12.8431","article-title":"Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara","volume":"175","author":"Smith","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib93","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi8635","article-title":"Fractionating a COVID-19 Ad5-vectored vaccine improves virus-specific immunity","volume":"6","author":"Sanchez","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib94","doi-asserted-by":"crossref","first-page":"10440","DOI":"10.1073\/pnas.1806314115","article-title":"TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination","volume":"115","author":"Bottermann","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.08.037_bib95","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.4049\/jimmunol.1301215","article-title":"Differential T cell responses to residual viral antigen prolong CD4+ T cell contraction following the resolution of infection","volume":"191","author":"Misumi","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib96","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1084\/jem.183.5.2259","article-title":"Induction of long-lived germinal centers associated with persisting antigen after viral infection","volume":"183","author":"Bachmann","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2025.08.037_bib97","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cell.2019.11.032","article-title":"Restricted Clonality and Limited Germinal Center Reentry Characterize Memory B Cell Reactivation by Boosting","volume":"180","author":"Mesin","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.08.037_bib98","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20161533","article-title":"Differentiation of germinal center B cells into plasma cells is initiated by high-affinity antigen and completed by Tfh cells","volume":"214","author":"Krautler","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2025.08.037_bib99","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1084\/jem.20060087","article-title":"Antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation","volume":"203","author":"Paus","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2025.08.037_bib100","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.immuni.2024.06.009","article-title":"Antibody modulation of B cell responses\u2014Incorporating positive and negative feedback","volume":"57","author":"Cyster","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.08.037_bib101","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.chom.2020.07.001","article-title":"Antibody Feedback Limits the Expansion of B Cell Responses to Malaria Vaccination but Drives Diversification of the Humoral Response","volume":"28","author":"McNamara","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ymthe.2025.08.037_bib102","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.immuni.2024.05.009","article-title":"Opposing effects of pre-existing antibody and memory T cell help on the dynamics of recall germinal centers","volume":"57","author":"Schiepers","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.08.037_bib103","series-title":"Vaccine Technologies for Veterinary Viral Diseases: Methods and Protocols","first-page":"177","article-title":"Generation and Selection of Orf Virus (ORFV) Recombinants","author":"Rziha","year":"2016"},{"key":"10.1016\/j.ymthe.2025.08.037_bib104","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.immuni.2023.01.029","article-title":"The alarmin interleukin-33 promotes the expansion and preserves the stemness of Tcf-1(+) CD8(+) T cells in chronic viral infection","volume":"56","author":"Marx","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.08.037_bib105","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.mt.6300306","article-title":"Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies","volume":"16","author":"Wortmann","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.037_bib106","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1099\/vir.0.82428-0","article-title":"Contributions of the lymphocytic choriomeningitis virus glycoprotein and polymerase to strain-specific differences in murine liver pathogenicity","volume":"88","author":"Bergthaler","year":"2007","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib107","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1128\/jvi.61.8.2509-2514.1987","article-title":"Antibodies against the two serotypes of vesicular stomatitis virus measured by enzyme-linked immunosorbent assay: immunodominance of serotype-specific determinants and induction of asymmetrically cross-reactive antibodies","volume":"61","author":"Charan","year":"1987","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025858","article-title":"A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon","volume":"6","author":"Berger Rentsch","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.08.037_bib109","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0166-0934(91)90018-U","article-title":"Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates","volume":"33","author":"Battegay","year":"1991","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.ymthe.2025.08.037_bib110","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.immuni.2017.11.023","article-title":"Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens","volume":"48","author":"Abbott","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.08.037_bib111","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1073\/pnas.1803457115","article-title":"Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity","volume":"115","author":"Dosenovic","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.08.037_bib112","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1126\/science.aaa1342","article-title":"Humoral immunity. Apoptosis and antigen affinity limit effector cell differentiation of a single naive B cell","volume":"347","author":"Taylor","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.08.037_bib113","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2108157118","article-title":"Vaccine-elicited CD4 T cells prevent the deletion of antiviral B cells in chronic infection","volume":"118","author":"Narr","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.08.037_bib114","first-page":"885","article-title":"The separation of different cell classes from lymphoid organs. VI. The effect of osmolarity of gradient media on the density distribution of cells","volume":"22","author":"Williams","year":"1972","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2025.08.037_bib115","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1128\/jvi.68.3.1573-1580.1994","article-title":"Characterization of T-helper epitopes of the glycoprotein of vesicular stomatitis virus","volume":"68","author":"Burkhart","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110061","article-title":"Vectored antibody gene delivery restores host B and T cell control of persistent viral infection","volume":"37","author":"Ertuna","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2025.08.037_bib117","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1084\/jem.151.5.1071","article-title":"Memory B cells at successive stages of differentiation. Affinity maturation and the role of IgD receptors","volume":"151","author":"Herzenberg","year":"1980","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2025.08.037_bib118","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-4939-2498-1_8","article-title":"Assessing T follicular helper cell function in vivo: antigen-specific B cell response to hapten and affinity maturation","volume":"1291","author":"Natt","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.08.037_bib119","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1078\/0344-0338-00166","article-title":"HOPE fixation: a novel fixing method and paraffin-embedding technique for human soft tissues","volume":"197","author":"Olert","year":"2001","journal-title":"Pathol. Res. Pract."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625006677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625006677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:22:57Z","timestamp":1779524577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625006677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":119,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1525001625006677"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.037","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Orf virus-based vectors induce potent germinal center B cell, Tfh cell, and CD8+ T cell responses","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}